JCP

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
[Advanced]

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Leeman, M F
Right arrow Articles by Murray, G I
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Leeman, M F
Right arrow Articles by Murray, G I
Journal of Clinical Pathology 2002;55:758-762
© 2002 Journal of Clinical Pathology


ORIGINAL ARTICLE

Matrix metalloproteinase 13 activity is associated with poor prognosis in colorectal cancer

M F Leeman1, J A McKay2, G I Murray1

1 Department of Pathology, University of Aberdeen, Aberdeen AB25 2ZD, UK
2 Department of Medicine and Therapeutics, University of Aberdeen

Correspondence to:
Dr G I Murray, Department of Pathology, University of Aberdeen, Foresterhill, Aberdeen AB25 2ZD, UK;
g.i.murray{at}abdn.ac.uk Aims: The matrix metalloproteinases (MMPs) are a family of proteolytic enzymes collectively capable of degrading all extracellular matrix components, in particular fibrillar collagen. The importance of this group of proteins in the processes of tumour invasion and metastasis is now widely acknowledged. MMP-13 (collagenase 3) has a central role in the MMP activation cascade. The purpose of this study was to investigate the presence and activity of MMP-13 in colorectal cancer and relate these to clinicopathological features.

Methods: Immunohistochemistry for MMP-13 was performed on formalin fixed, paraffin wax embedded sections of a large series of colorectal cancers (n = 249), all of which had uniform clinical and pathological information available. Immunoreactivity to MMP-13 was detected with a monoclonal antibody to MMP-13 using a Dako TechMateTM500 automated immunostaining system. The presence and cellular localisation of MMP-13 was assessed using a semiquantitative scoring system. Gelatin zymography was used to detect and measure MMP-13 activity. The zymography was performed on a subset of the cases studied by immunohistochemistry using two groups of 10 paired Dukes’s C tumours and normal samples, selected by either having "good" or "poor" survival.

Results: Immunoreactivity to MMP-13 was identified in 91% of cases and immunoreactivity was localised to the cytoplasm of tumour cells. A high MMP-13 staining score showed a trend towards poorer survival. Tumours had significantly greater MMP-13 activity compared with normal colonic mucosa (p < 0.001). Furthermore, the tumour to normal tissue ratio was significantly higher in the poor survival group (p = 0.02).

Conclusions: These results show that MMP-13 is frequently present and active in colorectal cancer and suggest that the activity of MMP-13 is associated with poorer survival in colorectal cancer.


Keywords: colorectal cancer; matrix metalloproteinase; tumour invasion

Abbreviations: AUC, area under the curve; ECM, extracellular matrix; MMP, matrix metalloproteinase; T/N ratio, tumour to normal tissue ratio




This article has been cited by other articles:


Home page
Clin. Cancer Res.Home page
M. S. Lyall, S. R. Dundas, S. Curran, and G. I. Murray
Profiling Markers of Prognosis in Colorectal Cancer
Clin. Cancer Res., February 15, 2006; 12(4): 1184 - 1191.
[Abstract] [Full Text] [PDF]


Home page
J. Cell Sci.Home page
D. Cavallo-Medved, J. Mai, J. Dosescu, M. Sameni, and B. F. Sloane
Caveolin-1 mediates the expression and localization of cathepsin B, pro-urokinase plasminogen activator and their cell-surface receptors in human colorectal carcinoma cells
J. Cell Sci., April 1, 2005; 118(7): 1493 - 1503.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
S. Curran, S. R. Dundas, J. Buxton, M. F. Leeman, R. Ramsay, and G. I. Murray
Matrix Metalloproteinase/Tissue Inhibitors of Matrix Metalloproteinase Phenotype Identifies Poor Prognosis Colorectal Cancers
Clin. Cancer Res., December 15, 2004; 10(24): 8229 - 8234.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Journal of Clinical Pathology Molecular Pathology
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2002 by the BMJ Publishing Group Ltd & Association of Clinical Pathologists.